Outcome of FOLFOX and Modified DCF Chemotherapy Regimen in Patients with Advanced Gastric Adenocarcinoma
| Autor: | Mohammad Molaei, Amin Danandeh Mehr, Afshin Habibzadeh, Mehdi Pourghasemian |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine medicine.medical_specialty medicine.medical_treatment Leucovorin Docetaxel Adenocarcinoma Gastroenterology 03 medical and health sciences 0302 clinical medicine FOLFOX Stomach Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Progression-free survival Survival rate Aged Retrospective Studies Chemotherapy business.industry General Medicine Middle Aged Prognosis Chemotherapy regimen digestive system diseases Oxaliplatin Survival Rate Regimen Cross-Sectional Studies 030104 developmental biology Lymphatic Metastasis 030220 oncology & carcinogenesis Female Fluorouracil Cisplatin business Follow-Up Studies Research Article medicine.drug |
| Zdroj: | Asian Pac J Cancer Prev |
| ISSN: | 2476-762X |
| DOI: | 10.31557/apjcp.2020.21.8.2337 |
| Popis: | Objectives Chemotherapy is used as an indispensable therapy for advanced gastric cancer. Different chemotherapy regimens have been used for this purpose. Toxicity due to the Chemotherapy drugs is one limiting factor. In this study we aim to compare the efficacy and toxicity of two regimens FOLFOX (leucoverin, 5-fluorouracil and oxaliplatin) and modified DCF (mDCF) (docetaxel, cisplatin, and 5-fluorouracil) in patients with advanced gastric adenocarcinoma. Methods In this analytical cross-sectional study, 47 patients treated with FOLFOX regimen and 57 patients treated with mDCF regimen were recruited, Patients in both groups were compared for demographic findings, response rate, mortality rate, overall survival (OS) and progression free survival (PFS). Results In FOLFOX and mDCF group, complete response (CR) occurred in 4.3% and 5.3%, partial response (PR) in 42.6% and 29.8%, stable disease in 34% and 52.6% and disease progression in 19.1% and 12.3%, respectively (p=0.25). Overall response rate was 48.9% and 56.1%, respectively. There was no significant difference between two regimens in OS and PFS (p=0.22). mDCF compared to FOLFOX had significantly higher hematologic, gastrointestinal complications, as well as creatinine rise, stomatitis and hair loss, but peripheral neuropathy was significantly lower. Conclusion The results of current study showed that in patients with advanced gastric adenocarcinoma, FOLFOX regimen compared to mDCF regimen have similar ORR, OS and PFS. Toxicity rate are also lower in FOLFOX group, thus it seems a better regimen for chemotherapy. . |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|